Nearly 48 million Americans - 1 in 6 people - had a substance use disorder in the past year, according to the most recent national survey data. That includes dependence on alcohol, illicit drugs, and prescription meds.

Earlier this past year, the DEA significantly increased production quotas for certain psychedelic drugs to support late-stage clinical trials for conditions like PTSD and treatment resistant depression. Such drugs include psilocybin, MDMA, LSD and DMT. 

In an age where mental health issues have become more prominent, the necessity for inpatient psychiatric care is evident. Inpatient psychiatric units are high-risk environments. Individuals experiencing psychological or psychiatric crises are in states of extreme vulnerability.